Neuromuscular blocking agents (NMBA) for COVID-19 acute respiratory distress syndrome: a multicenter observational study

Crit Care. 2020 Jul 19;24(1):446. doi: 10.1186/s13054-020-03164-2.
No abstract available

Publication types

  • Letter
  • Multicenter Study
  • Observational Study

MeSH terms

  • Aged
  • COVID-19
  • Coronavirus Infections / complications*
  • Coronavirus Infections / drug therapy*
  • Female
  • Humans
  • Male
  • Middle Aged
  • Neuromuscular Blocking Agents / therapeutic use*
  • Pandemics
  • Pneumonia, Viral / complications*
  • Pneumonia, Viral / drug therapy*
  • Prospective Studies
  • Respiratory Distress Syndrome / drug therapy*
  • Respiratory Distress Syndrome / virology*
  • Treatment Outcome

Substances

  • Neuromuscular Blocking Agents